Cytiva: Deliver What's Next: Fueling The Future of Autologous CAR T Therapy
Thursday, May 30, 2024 06:00 PM - 07:00 PM
Room 212-214
Corporate Session
Speakers
The development of CAR T cell therapies has been a decades-long journey from when the technology was first proposed in the late 1980s, to the Food and Drug Administration (FDA) approval of Novartis' Kymriah in 2017. Since then, 10 CAR T therapies have been approved worldwide and more than 20 000 patients have benefited from this revolutionary medicine. With over 1000 of such therapies in the clinical pipeline, the need for technologies that improve manufacturing productivity, automation, and scale-out capacity are even more critical to make these therapies less costly and widely accessible.
During this presentation, we’ll introduce a new platform that addresses the key challenges to manufacture autologous CAR T therapies at commercial scale. Discover how you will deliver what’s next. Session Objectives TBC
- Emmanuel Abate, President Genomic Medicine, Cytiva
- George White, Head of Product Management Cell Therapy, Cytiva
- Sadik Kassim, Chief Scientific/Technology Officer, Danaher Genomic Medicines
- Beate Meuller-Tiemann, Chief Technology Officer, Cytiva
- Martin Westberg, Vice President, Cell Therapy, Cytiva
- Angela Johnson, Global Regulatory & Compliance Executive Leader, Cytiva
The development of CAR T cell therapies has been a decades-long journey from when the technology was first proposed in the late 1980s, to the Food and Drug Administration (FDA) approval of Novartis' Kymriah in 2017. Since then, 10 CAR T therapies have been approved worldwide and more than 20 000 patients have benefited from this revolutionary medicine. With over 1000 of such therapies in the clinical pipeline, the need for technologies that improve manufacturing productivity, automation, and scale-out capacity are even more critical to make these therapies less costly and widely accessible.
During this presentation, we’ll introduce a new platform that addresses the key challenges to manufacture autologous CAR T therapies at commercial scale. Discover how you will deliver what’s next. Session Objectives TBC
SPONSORED BY:
